New Treatment Options in the Management of Relapsed/Refractory Hodgkin Lymphoma

This information was originally presented on September 14, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss the current treatment options for the management of patients with relapsed or refractory HL
  • Identify the rationale and need for the development of more effective treatment options for patients with relapsed/refractory HL
  • Review the clinical evidence from ongoing trials evaluating novel treatment options and the potential role of new agents in the treatment algorithm of HL
Additional information

Supported by educational grants from Genentech; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; and sanofi-aventis U.S.

Course summary
Available credit: 
  • 0.75 Participation
  • 0.71 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician
Course opens: 
Course expires: 

Leo I. Gordon, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Available Credit

  • 0.75 Participation
  • 0.71 Nurse
  • 0.75 Pharmacist
  • 0.75 Physician


Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing